ABSTRACT
Aortic stenosis (AS) and diabetes mellitus (DM) are both progressive diseases that if left untreated, result in significant morbidity and mortality. Several studies revealed that the prevalence of DM is substantially higher in patients with AS and, thus, the progression from mild to severe AS is greater in those patients with DM. DM and common comorbidities associated with both diseases, DM and AS, increase patient management complexity and make aortic valve replacement the only effective treatment. For that reason, a better understanding of the pathogenesis underlying both these diseases and the relationships between them is necessary to design more appropriate preventive and therapeutic approaches. In this review, we provided an overview of the main aspects of the relationship between AS and DM, including common comorbidities and risk factors. We also discuss the established treatments/therapies in patients with AS and DM.
Subject(s)
Aortic Valve Stenosis , Aortic Valve Stenosis/etiology , Aortic Valve Stenosis/metabolism , Aortic Valve Stenosis/pathology , Aortic Valve Stenosis/therapy , Diabetes Complications/metabolism , Diabetes Complications/pathology , Diabetes Complications/therapy , Humans , Risk FactorsSubject(s)
Atrial Appendage , Atrial Fibrillation , Cardiac Surgical Procedures , Stroke , Thrombosis , Atrial Appendage/diagnostic imaging , Atrial Appendage/surgery , Atrial Fibrillation/complications , Atrial Fibrillation/surgery , Echocardiography, Transesophageal , Humans , Stroke/etiology , Stroke/prevention & control , Thrombosis/etiology , Treatment OutcomeABSTRACT
Aortic stenosis is the most frequent valvular disease in developed countries. It progresses from mild fibrocalcific leaflet changes to a more severe leaflet calcification at the end stages of the disease. Unfortunately, symptoms of aortic stenosis are unspecific and only appear when it is too late, complicating patients' management. The global impact of aortic stenosis is increasing due to the growing elderly population. The disease supposes a great challenge because of the multiple comorbidities of these patients. Nowadays, the only effective treatment is valve replacement, which has a high cost in both social and economic terms. For that reason, it is crucial to find potential diagnostic, prognostic and therapeutic indicators that could help us to detect this disease in its earliest stages. In this article, we comprehensively review several key observations and translational studies related to protein markers that are promising for being implemented in the clinical field as well as a discussion about the role of precision medicine in aortic stenosis.
ABSTRACT
BACKGROUND: Dilated cardiomyopathy is associated with increased risk of major cardiovascular events. Late gadolinium enhancement (LGE) cardiac magnetic resonance imaging is a unique tissue-based marker that, in single-center studies, suggests strong prognostic value. We retrospectively studied associations between LGE presence and adverse cardiovascular events in patients with dilated cardiomyopathy in a multicenter setting as part of an emerging global consortium (MINICOR [Multi-Modal International Cardiovascular Outcomes Registry]). METHODS: Consecutive patients with dilated cardiomyopathy referred for cardiac magnetic resonance (2000-2017) at 12 institutions in 4 countries were studied. Using multivariable Cox proportional hazard and semiparametric Fine and Gray models, we evaluated the association between LGE and the composite primary end point of all-cause mortality, heart transplantation, or left ventricular assist device implant and a secondary arrhythmic end point of sudden cardiac death or appropriate implantable cardioverter-defibrillator shock. RESULTS: We studied 1672 patients, mean age 56±14 years (29% female), left ventricular ejection fraction 33±11%, and 25% having New York Heart Association class III to IV; 650 patients (39%) had LGE. During 2.3 years (interquartile range, 1.0-4.3) follow-up, 160 patients experienced the primary end point, and 88 experienced the arrhythmic end point. In multivariable analyses, LGE was associated with 1.5-fold (hazard ratio, 1.45 [95% CI, 1.03-2.04]) risk of the primary end point and 1.8-fold (hazard ratio, 1.82 [95% CI, 1.20-3.06]) risk of the arrhythmic end point. Primary end point risk was increased in patients with multiple LGE patterns, although arrhythmic risk was higher among patients receiving primary prevention implantable cardioverter-defibrillator and widening QRS. CONCLUSIONS: In this large multinational study of patients with dilated cardiomyopathy, the presence of LGE showed strong prognostic value for identification of high-risk patients. Randomized controlled trials evaluating LGE-based care management strategies are warranted.
Subject(s)
Cardiomyopathy, Dilated/diagnostic imaging , Contrast Media/pharmacokinetics , Gadolinium/pharmacokinetics , Image Enhancement/methods , Magnetic Resonance Imaging/methods , Patient Outcome Assessment , Aged , Canada , Cohort Studies , Female , Heart/diagnostic imaging , Humans , Italy , Male , Middle Aged , Predictive Value of Tests , Prognosis , Retrospective Studies , Spain , Time , United StatesABSTRACT
No disponible
Subject(s)
Humans , Male , Aged, 80 and over , Mitral Valve Insufficiency/surgery , Heart Valve Prosthesis Implantation/methods , Graft Occlusion, Vascular/diagnostic imaging , Prosthesis FailureSubject(s)
Heart Valve Diseases/diagnosis , Heart Valve Prosthesis/adverse effects , Mitral Valve/diagnostic imaging , Postoperative Complications/diagnosis , Tomography, X-Ray Computed/methods , Aged, 80 and over , Echocardiography, Transesophageal , Heart Valve Diseases/surgery , Humans , Male , Mitral Valve/surgery , Mitral Valve Insufficiency/diagnosis , Mitral Valve Insufficiency/surgery , ReoperationABSTRACT
No disponible
Subject(s)
Humans , Female , Adult , Alstrom Syndrome/complications , Cardiomyopathy, Dilated/diagnosis , Ventricular Dysfunction, Left/diagnosis , Genetic Testing/methodsABSTRACT
No disponible
